

PRODUCT DATA SHEET



Bioworld Technology, Inc.

Recombinant GRO/MGSA/CXCL1, Human

Catalog Number: BK0215-1mg

Source: CHO

Quantity: 1mg

Description:

GRO/MGSA/CXCL1 has chemotactic activity for neutrophils. It may play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. All three isoforms of GRO are CXC chemokines that can signal through the CXCR1 or CXCR2 receptors. GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.

Molecular Weight:

~7.8 kDa, observed by reducing SDS-PAGE.

Purity:

> 95% as analyzed by SDS-PAGE.

Biological Activity:

Active, measured in a functional assay using HUVEC cells.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Lyophilized after extensive dialysis against PBS.

AA Sequence:

ASVATELRCQCLQTLQGIHPKNIQSVNVK-
SPGPHCAQTEVIATLKNRKA CLNPASPIV-
KKIIEKMLNSDKSN

Endotoxin:

< 0.2 EU/μg, determined by LAL method.

Reconstitution:

Reconstituted in ddH₂O or PBS at 100 μg/ml.

Storage:

Lyophilized recombinant Human GRO/MGSA/CXCL1 remains stable up to 6 months at -80 °C from date of receipt. Upon reconstitution, Human GRO/MGSA/CXCL1 should be stable up to 1 week at 4 °C or up to 2 months at -20 °C.

Usage:

This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. For research use only.